Earnings Call · Q2 FY2023·2023-08-07

Q2 23EPS +23.93%·Rev n/aQ1 23EPS -49.17%·Rev n/aQ4 22EPS +33.87%·Rev n/aQ3 22EPS +20.25%·Rev n/a⚠ consensus missing

Quoin Pharmaceuticals Ltd. QNRX

Gordon Dunn — CFO

Michael Myers — CEO

+6.3%1d on move date+6.5% vs SPY3d−13.0%5d−13.7%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more QNRX calls or request research access.

More QNRX calls Browse calls Request research access